Earlier this month, Morgan Stanley and Raymond James upgraded Doximity after highlighting its strong free cash flow, balance sheet strength, and expanded AI-enabled workflow tools that are ...

Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...

A US pharmaceutical company reached a $1.5 trillion valuation last week, joining a club that up until now had been exclusively occupied by artificial intelligence businesses. The company was Eli Lilly ...

Despite economic uncertainty and a steady flow of takeovers and overseas departures, UK equities have staged a strong recovery. AJ Bell investment director ...

Dividend stocks (which commonly are value stocks, but can be growth stocks) are great ways to drive long-term performance of ...

Switzerland is preparing to tighten scrutiny of selected foreign investments, a notable shift for a country that has long marketed itself as one of the world's most open destinations for cross-border ...

President Trump’s Food and Drug Administration is cracking down on the “endless” barrage of pharmaceutical advertisements Americans are hit with on a daily basis, FDA Commissioner Marty Makary said on ...

This combination of growth and value stocks has the tools and intangibles necessary to outperform in the year to come.

As the Australian stock market opens modestly higher, buoyed by a late Christmas rally in the U.S., investors are keeping an eye on precious metals and currency movements that are providing a boost to ...

Australia's economy expanded 0.4 per cent in the September quarter, coming in below forecasts. But economists say the detail is stronger than the headline indicates. Look back on how the trading day ...